Illana Gozes
#126,147
Most Influential Person Now
Researcher ORCID ID = 0000-0001-9796-2430
Illana Gozes's AcademicInfluence.com Rankings
Illana Gozesbiology Degrees
Biology
#7981
World Rank
#10986
Historical Rank
Neuroscience
#1080
World Rank
#1122
Historical Rank
Download Badge
Biology
Illana Gozes's Degrees
- PhD Neuroscience Tel Aviv University
- Masters Biology Tel Aviv University
- Bachelors Biology Tel Aviv University
Similar Degrees You Can Earn
Why Is Illana Gozes Influential?
(Suggest an Edit or Addition)Illana Gozes's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (2012) (2913)
- Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1 (2021) (811)
- Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase‐activating polypeptide: IUPHAR Review 1 (2012) (376)
- Complete Sequence of a Novel Protein Containing a Femtomolar‐Activity‐Dependent Neuroprotective Peptide (1999) (339)
- Growth factor function of vasoactive intestinal peptide in whole cultured mouse embryos (1993) (275)
- A femtomolar-acting neuroprotective peptide. (1996) (258)
- Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial (2014) (231)
- A Glia-Derived Signal Regulating Neuronal Differentiation (2000) (220)
- A peptide derived from activity-dependent neuroprotective protein (ADNP) ameliorates injury response in closed head injury in mice. (2001) (217)
- A Neuronal Microtubule-Interacting Agent, NAPVSIPQ, Reduces Tau Pathology and Enhances Cognitive Function in a Mouse Model of Alzheimer's Disease (2008) (210)
- Tubulin microheterogeneity increases with rat brain maturation (1978) (207)
- Activity-dependent neuroprotective protein: a novel gene essential for brain formation. (2003) (204)
- Cytokine Regulation of Neuronal Survival (1992) (204)
- Cloning and Characterization of the Human Activity-dependent Neuroprotective Protein* (2001) (200)
- Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-activating Polypeptide Inhibit Tumor Necrosis Factor α Transcriptional Activation by Regulating Nuclear Factor-kB and cAMP Response Element-binding Protein/c-Jun* (1998) (192)
- Activity-Dependent Neuroprotective Protein Snippet NAP Reduces Tau Hyperphosphorylation and Enhances Learning in a Novel Transgenic Mouse Model (2007) (185)
- Prevention of fetal demise and growth restriction in a mouse model of fetal alcohol syndrome. (2001) (182)
- Neuroprotective strategy for Alzheimer disease: intranasal administration of a fatty neuropeptide. (1996) (176)
- Vasoactive intestinal peptide prevents excitotoxic cell death in the murine developing brain. (1997) (174)
- Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage (2007) (164)
- Autophagy has a key role in the pathophysiology of schizophrenia (2013) (161)
- Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a water maze. (2000) (161)
- Tubulin: An Integral Protein of Mammalian Synaptic Vesicle Membranes (1980) (152)
- An antagonist to vasoactive intestinal peptide affects cellular functions in the central nervous system. (1991) (151)
- Learning impairment following intracerebral administration of the HIV envelope protein gp120 or a VIP antagonist (1992) (150)
- Activity-dependent neuroprotective protein (ADNP) differentially interacts with chromatin to regulate genes essential for embryogenesis. (2007) (135)
- Vasoactive Intestinal Peptide and Pituitary Adenylyl Cyclase-Activating Polypeptide Inhibit Tumor Necrosis Factor-α Production in Injured Spinal Cord and in Activated Microglia via a cAMP-Dependent Pathway (2000) (134)
- NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). (2006) (133)
- Experimental intrauterine growth retardation alters renal development (2000) (133)
- Cancer-associated stroke: Pathophysiology, detection and management (Review) (2019) (131)
- A Femtomolar Acting Octapeptide Interacts with Tubulin and Protects Astrocytes against Zinc Intoxication* (2004) (130)
- Activity-dependent neurotrophic factor: structure-activity relationships of femtomolar-acting peptides. (1998) (127)
- A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth. (1993) (124)
- Severe microcephaly induced by blockade of vasoactive intestinal peptide function in the primitive neuroepithelium of the mouse. (1994) (119)
- Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease 1 This manuscript is based on a poster presented at the Brain Research Interactive Symposium on “Neuropeptides at the Millennium”, Miami, October 1999. 1 (2000) (119)
- Multiple tubulin forms are expressed by a single neurone (1981) (118)
- Activity-dependent Neuroprotective Protein Constitutes a Novel Element in the SWI/SNF Chromatin Remodeling Complex* (2007) (116)
- NAP, a Femtomolar-Acting Peptide, Protects the Brain Against Ischemic Injury by Reducing Apoptotic Death (2002) (113)
- NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model (2009) (112)
- Vasoactive intestinal peptide potentiates sexual behavior: Inhibition by novel antagonist (1989) (104)
- Peptide neuroprotection through specific interaction with brain tubulin (2006) (103)
- Monoclonal antibodies that recognize discrete forms of tubulin. (1982) (101)
- Decrease in levels and rates of synthesis of tubulin and actin in developing rat brain (1977) (101)
- Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist. (1996) (100)
- Superactive lipophilic peptides discriminate multiple vasoactive intestinal peptide receptors. (1995) (100)
- Steroid regulation of somatostatin mRNA in the rat hypothalamus. (1988) (94)
- Addressing Alzheimer's disease tangles: from NAP to AL-108. (2009) (92)
- NAP (davunetide) modifies disease progression in a mouse model of severe neurodegeneration: Protection against impairments in axonal transport (2013) (91)
- Neuroprotective peptide drug delivery and development: potential new therapeutics (2001) (88)
- Subcellular localization and secretion of activity-dependent neuroprotective protein in astrocytes. (2004) (87)
- Clinical Presentation of a Complex Neurodevelopmental Disorder Caused by Mutations in ADNP (2019) (85)
- Coding sequences for vasoactive intestinal peptide and PHM-27 peptide are located on two adjacent exons in the human genome. (1985) (85)
- Interleukin-1 alpha and vasoactive interstinal peptide: Enigmatic regulation of neuronal survival (1995) (83)
- The femtomolar-acting NAP interacts with microtubules: Novel aspects of astrocyte protection. (2005) (83)
- The neuroprotective peptide NAP inhibits the aggregation of the beta-amyloid peptide (2003) (81)
- Differential regulation of activity-dependent neuroprotective protein in rat astrocytes by VIP and PACAP (2004) (80)
- VIP: Molecular biology and neurobiological function (2007) (80)
- Intranasal administration of NAP, a neuroprotective peptide, decreases anxiety-like behavior in aging mice in the elevated plus maze (2004) (79)
- Activity-dependent neuroprotective protein (ADNP) exhibits striking sexual dichotomy impacting on autistic and Alzheimer's pathologies (2015) (78)
- NAP, a neuroprotective drug candidate in clinical trials, stimulates microtubule assembly in the living cell. (2007) (78)
- PolyADP-Ribosylation Is Involved in Neurotrophic Activity (2005) (77)
- Pharmaceutical VIP: prospects and problems. (1999) (76)
- Vasoactive intestinal peptide antagonist retards the development of neonatal behaviors in the rat (1991) (76)
- The ADNP Derived Peptide, NAP Modulates the Tubulin Pool: Implication for Neurotrophic and Neuroprotective Activities (2012) (76)
- SIRT1, miR-132 and miR-212 link human longevity to Alzheimer’s Disease (2018) (71)
- ADNP Differential Nucleus/Cytoplasm Localization in Neurons Suggests Multiple Roles in Neuronal Differentiation and Maintenance (2008) (71)
- A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions (2011) (67)
- Activity-dependent neurotrophic factor-9 and NAP promote neurite outgrowth in rat hippocampal and cortical cultures (2007) (67)
- A Novel peptide prevents death in enriched neuronal cultures (2000) (67)
- The α‐subunit of tubulin is preferentially associated with brain presynaptic membrane (1979) (67)
- Vasoactive intestinal peptide gene expression from embryos to aging rats. (1988) (66)
- PolyADP‐ribosylation is required for long‐term memory formation in mammals (2009) (65)
- Activity-dependent neuroprotective protein: from gene to drug candidate. (2007) (64)
- Activity‐Dependent Neurotrophic Factor Peptide (ADNF9) Protects Neurons Against Oxidative Stress‐Induced Death (1999) (63)
- CREB contributes to the increased neurite outgrowth of sensory neurons induced by vasoactive intestinal polypeptide and activity-dependent neurotrophic factor (2000) (63)
- Protection against developmental retardation in apolipoprotein E-deficient mice by a fatty neuropeptide: implications for early treatment of Alzheimer's disease. (1997) (63)
- A VIP antagonist distinguishes VIP receptors on spinal cord cells and lymphocytes (1991) (62)
- The peptides ADNF-9 and NAP increase survival and neurite outgrowth of rat retinal ganglion cells in vitro. (2005) (61)
- VIP and peptides related to activity-dependent neurotrophic factor protect PC12 cells against oxidative stress (2000) (61)
- New horizons in schizophrenia treatment: autophagy protection is coupled with behavioral improvements in a mouse model of schizophrenia (2014) (61)
- Complex array of cytokines released by vasoactive intestinal peptide (2003) (60)
- Mapping the active site in vasoactive intestinal peptide to a core of four amino acids: neuroprotective drug design. (1999) (59)
- ADNP/NAP dramatically increase microtubule end-binding protein–Tau interaction: a novel avenue for protection against tauopathy (2017) (59)
- Activity-dependent neuroprotective protein (ADNP) expression level is correlated with the expression of the sister protein ADNP2: Deregulation in schizophrenia (2011) (59)
- NAP and D-SAL: neuroprotection against the β amyloid peptide (1–42) (2008) (59)
- The identification of secreted heat shock 60 -like protein from rat glial cells and a human neuroblastoma cell line (1998) (58)
- From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP (2007) (58)
- Activity-dependent neuroprotective protein deficiency models synaptic and developmental phenotypes of autism-like syndrome (2018) (57)
- Protective Peptides That Are Orally Active and Mechanistically Nonchiral (2004) (57)
- NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse—A microtubule-deficient model of schizophrenia (2010) (57)
- High levels of vasoactive intestinal peptide in human milk. (1985) (56)
- Translation in vitro of rat brain messenger RNA coding for tubulin and actin. (1975) (56)
- Developmental expression of the VIP-gene in brain and intestine. (1987) (56)
- Antiserum to activity-dependent neurotrophic factor produces neuronal cell death in CNS cultures: immunological and biological specificity. (1997) (55)
- Involvement of Pituitary Adenylate Cyclase‐Activating Polypeptide II Vasoactive Intestinal Peptide 2 Receptor in Mouse Neocortical Astrocytogenesis (1998) (55)
- A Novel Signaling Molecule for Neuropeptide Action: Activity‐dependent Neuroprotective Protein (1999) (55)
- Translation in vitro of rat brain mRNA coding for a variety of tubulin forms. (1980) (55)
- A new concept in the pharmacology of neuroprotection (2000) (54)
- NAP mechanisms of neuroprotection (2007) (54)
- NAP and ADNF-9 protect normal and Down's syndrome cortical neurons from oxidative damage and apoptosis. (2007) (53)
- Davunetide (NAP) as a preventative treatment for central nervous system complications in a diabetes rat model (2011) (52)
- Discovery of autism/intellectual disability somatic mutations in Alzheimer's brains: mutated ADNP cytoskeletal impairments and repair as a case study (2019) (51)
- NAP (davunetide) provides functional and structural neuroprotection. (2011) (51)
- Neuroprotection of the developing brain by systemic administration of vasoactive intestinal peptide derivatives. (1999) (51)
- Blood-Borne Activity-Dependent Neuroprotective Protein (ADNP) is Correlated with Premorbid Intelligence, Clinical Stage, and Alzheimer's Disease Biomarkers. (2015) (50)
- Tubulin microheterogeneity in neuroblastoma and glioma cell lines differs from that of the brain (1979) (49)
- VIP-related protection against lodoacetate toxicity in pheochromocytoma (PC12) cells (2000) (49)
- Stearyl-norleucine-vasoactive intestinal peptide (VIP): a novel VIP analog for noninvasive impotence treatment. (1994) (49)
- The expression of activity-dependent neuroprotective protein (ADNP) is regulated by brain damage and treatment of mice with the ADNP derived peptide, NAP, reduces the severity of traumatic head injury. (2005) (49)
- The complete structure of the rat VIP gene. (1990) (48)
- Vasoactive intestinal peptide receptors: a molecular target in breast and lung cancer. (2007) (48)
- Neurobehavioral Development of Neonatal Mice Following Blockade of VIP During the Early Embryonic Period (1997) (48)
- Spontaneous electrical activity regulates vasoactive intestinal peptide expression in dissociated spinal cord cell cultures. (1991) (47)
- A femtomolar-acting neuroprotective peptide induces increased levels of heat shock protein 60 in rat cortical neurons: a potential neuroprotective mechanism (1999) (47)
- Identification of VIP/PACAP receptors on rat astrocytes using antisense oligodeoxynucleotides (1997) (47)
- Recombinant activity-dependent neuroprotective protein protects cells against oxidative stress (2006) (46)
- Novel Marker for the Onset of Frontotemporal Dementia: Early Increase in Activity-Dependent Neuroprotective Protein (ADNP) in the Face of Tau Mutation (2014) (46)
- VIP receptor antagonists and chemotherapeutic drugs inhibit the growth of breast cancer cells (2001) (45)
- Identity of Neurotrophic Molecules Released from Astroglia by Vasoactive Intestinal Peptide a (1997) (45)
- Translation in vitro of carnation mottle virus RNA. Regulatory function of the 3'-region. (1978) (44)
- Brain deficits associated with fetal alcohol exposure may be protected, in part, by peptides derived from activity-dependent neurotrophic factor and activity-dependent neuroprotective protein (2006) (44)
- Detection of vasoactive intestinal peptide-encoding messenger ribonucleic acid in the rat ovaries. (1986) (44)
- Activity-dependent neurotrophic factor (ADNF). An extracellular neuroprotective chaperonin? (1996) (43)
- Microtubules (tau) as an emerging therapeutic target: NAP (davunetide). (2011) (43)
- VIP Neurotrophism in the Central Nervous System: Multiple Effectors and Identification of a Femtomolar‐Acting Neuroprotective Peptide (1998) (43)
- Sexual dimorphism of activity-dependent neuroprotective protein in the mouse arcuate nucleus (2004) (43)
- Novel Evolutionary-conserved Role for the Activity-dependent Neuroprotective Protein (ADNP) Family That Is Important for Erythropoiesis* (2012) (42)
- Lactation elevates vasoactive intestinal peptide messenger ribonucleic acid in rat suprachiasmatic nucleus. (1989) (42)
- Tau pathology and future therapeutics. (2010) (42)
- Tau and Caspase 3 as Targets for Neuroprotection (2012) (42)
- Synthesis of tubulin and actin by neuronal and glial nuclear preparations from devloping rat brain. (1977) (42)
- Distribution of cells expressing vasoactive intestinal peptide/peptide histidine isoleucine-amide precursor messenger rna in the rat brain (1992) (41)
- Tauopathy in the young autistic brain: novel biomarker and therapeutic target (2020) (41)
- Intranasal NAP (davunetide) decreases tau hyperphosphorylation and moderately improves behavioral deficits in mice overexpressing α-synuclein (2014) (40)
- Vasoactive intestinal peptide: a growth promotor in neuroblastoma cells (1993) (40)
- VIP and the potent analog, stearyl‐Nle17‐VIP, induce proliferation of keratinocytes (2000) (40)
- Microtubule-stabilizing peptides and small molecules protecting axonal transport and brain function: Focus on davunetide (NAP) (2013) (39)
- VIP and drug design. (2003) (38)
- A Novel VIP Responsive Gene: Activity Dependent Neuroprotective Protein (2000) (38)
- NAP Enhances Neurodevelopment of Newborn Apolipoprotein E-Deficient Mice Subjected to Hypoxia (2006) (38)
- Hormonal regulation of somatostatin messenger RNA (1988) (38)
- The Compassionate Side of Neuroscience: Tony Sermone’s Undiagnosed Genetic Journey—ADNP Mutation (2015) (38)
- Pharmacologically distinct vasoactive intestinal peptide binding sites: CNS localization and role in embryonic growth (1999) (38)
- Identification of tubulin associated with rat brain myelin (1978) (37)
- Structure and expression of the vasoactive intestinal peptide (VIP) gene in a human tumor (1986) (37)
- Davunetide: Peptide therapeutic in neurological disorders. (2014) (37)
- NAP accelerates the performance of normal rats in the water maze (2002) (37)
- The autism/neuroprotection-linked ADNP/NAP regulate the excitatory glutamatergic synapse (2019) (36)
- Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects. (2011) (36)
- Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy (2012) (36)
- NAP, a Peptide Derived from the Activity‐Dependent Neuroprotective Protein, Modulates Macrophage Function (2006) (36)
- A fatty neuropeptide. Potential drug for noninvasive impotence treatment in a rat model. (1992) (35)
- ADNP Plays a Key Role in Autophagy: From Autism to Schizophrenia and Alzheimer's Disease (2017) (35)
- NAP protects against cytochrome c release: inhibition of the initiation of apoptosis. (2009) (35)
- Adenylyl cyclase activating polypeptide reduces phosphorylation and toxicity of the polyglutamine-expanded androgen receptor in spinobulbar muscular atrophy (2016) (35)
- Learning and sexual deficiencies in transgenic mice carrying a chimeric vasoactive intestinal peptide gene (2007) (35)
- Blockade of VIP during Neonatal Development Induces Neuronal Damage and Increases VIP and VIP Receptors in Brain (1994) (34)
- The blood-brain barrier and beyond: Nano-based neuropharmacology and the role of extracellular matrix. (2019) (34)
- Hypothalamic vasoactive intestinal peptide messenger ribonucleic acid is increased in lactating rats. (1986) (34)
- VIP-mRNA is increased in hypertensive rats (1989) (34)
- Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356 (2016) (33)
- Vasoactive intestinal peptide and related molecules induce nitrite accumulation in the extracellular milieu of rat cerebral cortical cultures (2001) (33)
- Localization of vasopressin-, vasoactive intestinal polypeptide-, peptide histidine isoleucine-and somatostatin-mRNA in rat suprachiasmatic nucleus (1988) (33)
- VIP analogues inhibit small cell lung cancer growth (1992) (33)
- Immunochemical determination of tubulin (1977) (33)
- Tubulin in the nervous system (1982) (32)
- VIP provides cellular protection through a specific splice variant of the PACAP receptor: A new neuroprotection target (2006) (32)
- VIP and Breast Cancer (1998) (32)
- The octapetide NAP alleviates intestinal and extra-intestinal anti-inflammatory sequelae of acute experimental colitis (2018) (32)
- Diurnal oscillation in vasoactive intestinal peptide gene expression independent of environmental light entraining (1994) (31)
- Editorial :Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). DOI: 10.1080/15548627.2015.1100356;WOS:000373595400001; 2-s2.0-85013763791&;PMID: 26799652 (2016) (31)
- A lipophilic vasoactive intestinal peptide analog enhances the antiproliferative effect of chemotherapeutic agents on cancer cell lines (2001) (31)
- Silencing of the ADNP‐family member, ADNP2, results in changes in cellular viability under oxidative stress (2008) (31)
- The Eight and a Half Year Journey of Undiagnosed AD: Gene Sequencing and Funding of Advanced Genetic Testing Has Led to Hope and New Beginnings (2017) (30)
- Brain injury-dependent expression of activity-dependent neuroprotective protein (2007) (30)
- Activity-dependent neuroprotective protein (ADNP): a case study for highly conserved chordata-specific genes shaping the brain and mutated in cancer. (2015) (30)
- (Stearyl, Norleucine17)VIP hybrid antagonizes VIP receptors on non-small cell lung cancer cells. (1997) (30)
- Vasoactive intestinal peptide inhibits cytokine production in T lymphocytes through cAMP-dependent and cAMP-independent mechanisms (1999) (30)
- The Pregnant Spontaneously Hypertensive Rat as a Model of Asymmetric Intrauterine Growth Retardation and Neurodevelopmental Delay (2005) (30)
- Vasoactive Intestinal Peptide: Link between Electrical Activity and Glia‐mediated Neurotrophism (1999) (29)
- Inhibition of murine embryonic growth by human immunodeficiency virus envelope protein and its prevention by vasoactive intestinal peptide and activity-dependent neurotrophic factor. (1997) (29)
- The survival of dentate gyrus neurons in dissociated culture. (1987) (28)
- Localization of VIP and PHI-27 messenger RNA in rat thalamic and cortical neurons. (1989) (28)
- Risperidone and NAP protect cognition and normalize gene expression in a schizophrenia mouse model (2015) (28)
- Developmental expression of the VIP-gene in brain and intestine (1987) (28)
- Locomotor activity causes a rapid up‐regulation of vasoactive intestinal peptide in the rat hippocampus (1999) (28)
- NAP (davunetide) preferential interaction with dynamic 3-repeat Tau explains differential protection in selected tauopathies (2018) (28)
- VIP, From Gene to Behavior and Back: Summarizing my 25 Years of Research (2008) (28)
- A single administration of the peptide NAP induces long-term protective changes against the consequences of head injury (2002) (27)
- Conditioned media from activated lymphocytes maintain sympathetic neurons in culture. (1982) (27)
- The VIP gene is expressed in non-small cell lung cancer cell lines (1992) (27)
- Clinical endocrinology and metabolism. Potential clinical applications of vasoactive intestinal peptide: a selected update. (2004) (27)
- Activity-dependent neurotrophic factor: a potent regulator of embryonic growth and development (1999) (27)
- Sequential expression in the nervous system of C-MYB andVIP genes, located in human chromosomal region 6q24 (1987) (27)
- NAP Alpha-Aminoisobutyric Acid (IsoNAP) (2013) (26)
- Vasoactive Intestinal Peptide (VIP) Regulates Activity-Dependent Neuroprotective Protein (ADNP) Expression In Vivo (2007) (26)
- In vitro and in vivo treatment of colon cancer by VIP antagonists (2002) (26)
- The effects of vascular intrauterine growth retardation on cortical astrocytes. (2010) (26)
- Blockage of VIP during mouse embryogenesis modifies adult behavior and results in permanent changes in brain chemistry (2007) (26)
- Activity-Dependent Neuroprotective Protein (ADNP) Expression in the Amyloid Precursor Protein/Presenilin 1 Mouse Model of Alzheimer’s Disease (2010) (26)
- IGF-I as a mediator of VIP/activity-dependent neurotrophic factor-stimulated embryonic growth. (2001) (25)
- Disruption of the optic pathway during development affects vasoactive intestinal peptide mRNA expression. (1989) (25)
- Novel tubulin and tau neuroprotective fragments sharing structural similarities with the drug candidate NAP (Davuentide). (2014) (25)
- Cellular and animal models of skin alterations in the autism-related ADNP syndrome (2019) (25)
- Neurotrophic effects of the peptide NAP: a novel neuroprotective drug candidate. (2006) (25)
- SNV, a lipophilic superactive VIP analog, acts through cGMP to promote neuronal survival (1999) (25)
- Davunetide Pharmacokinetics and distribution to brain after intravenous or intranasal administration to rat (2009) (25)
- The autism-mutated ADNP plays a key role in stress response (2019) (24)
- A vasoactive intestinal peptide antagonist inhibits the growth of glioblastoma cells (2001) (24)
- Detection of mRNAs containing regulatory peptide coding sequences using synthetic oligodeoxynucleotides (1984) (24)
- Tubulin is the target binding site for NAP-related peptides (2007) (23)
- Vasoactive intestinal peptide: a growth promoter in neuroblastoma cells. (1993) (23)
- Estrogen regulation of vasoactive intestinal peptide mRNA in rat hypothalamus (2008) (23)
- A Novel Method for Analyzing Mitochondrial Movement: Inhibition by Paclitaxel in a Pheochromocytoma Cell Model (2009) (23)
- The microtubule interacting drug candidate NAP protects against kainic acid toxicity in a rat model of epilepsy (2009) (23)
- Microtubules, schizophrenia and cognitive behavior: Preclinical development of davunetide (NAP) as a peptide-drug candidate (2011) (22)
- Activity-dependent neurotrophic factor (ADNF) (2007) (22)
- The influence of the peptide NAP on Mac-1-deficient mice following closed head injury (2005) (22)
- (N-stearyl, norleucine17) VIP hybrid inhibits the growth of pancreatic cancer cell lines. (1999) (22)
- Differential expression of embryonic and maternal activity-dependent neuroprotective protein during mouse development. (2002) (21)
- Reduction of aluminum ion neurotoxicity through a small peptide application – NAP treatment of Alzheimer’s disease (2019) (21)
- RGS2 expression predicts amyloid-β sensitivity, MCI and Alzheimer's disease: genome-wide transcriptomic profiling and bioinformatics data mining (2016) (21)
- (N-stearyl, norleucine17) VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist (2002) (21)
- Neuropeptides and Neuronal Survival: Neuroprotective Strategy for Alzheimer's Disease a (1997) (21)
- Neuropeptides as growth and differentiation factors in general and VIP in particular (2007) (21)
- Looking for novel ways to treat the hallmarks of Alzheimer's disease (2007) (20)
- Novel glycosylated VIP analogs: synthesis, biological activity, and metabolic stability (2008) (20)
- Protective peptides derived from novel glial proteins. (2000) (20)
- Parkinson’s and Alzheimer’s diseases (2007) (20)
- Injections of the neuroprotective peptide NAP to newborn mice attenuate head-injury-related dysfunction in adults (2003) (20)
- Studies toward the biosynthesis of vasoactive intestinal peptide (VIP) (1984) (19)
- The ADNP Syndrome and CP201 (NAP) Potential and Hope (2020) (18)
- Monoclonal Antibodies Against Vasoactive Intestinal Polypeptide: Studies of Structure and Related Antigens (1983) (18)
- PACAP hybrid: a new PACAP receptor antagonist. (1997) (18)
- Ameliorative effect of NAP on laser‐induced retinal damage (2011) (18)
- Adrenalectomy decreases vasoactive intestinal peptide mRNA levels in the rat suprachiasmatic nucleus (1994) (18)
- D-NAP Prophylactic Treatment in the SOD Mutant Mouse Model of Amyotrophic Lateral Sclerosis: Review of Discovery and Treatment of Tauopathy (2012) (18)
- Inhibition of human neuroblastoma growth by a specific VIP antagonist (2007) (18)
- The cytoskeleton as a drug target for neuroprotection: the case of the autism- mutated ADNP (2016) (18)
- Protein Synthesis in Rat Brain Microvessels Decreases with Aging (1981) (17)
- Neuroprotective Protein and Carboxypeptidase E (2009) (17)
- The gene encoding vasoactive intestinal peptide is located on human chromosome 6p21→6qter (1987) (17)
- Vasoactive Intestinal Peptide Regulates Embryonic Growth Through the Action of Activity‐dependent Neurotrophic Factor (1999) (17)
- VIP‐derived sequences modified by N‐terminal stearyl moiety induce cell death: the human keratinocyte as a model (2000) (17)
- A VIP hybrid antagonist: From developmental neurobiology to clinical applications (1995) (17)
- Developmental Phenotype of the Rare Case of DJ Caused by a Unique ADNP Gene De Novo Mutation (2019) (17)
- A possible high molecular weight precursor to vasoactive intestinal polypeptide sequestered into pheochromocytoma chromaffin granules (1983) (17)
- Introducing ADNP and SIRT1 as new partners regulating microtubules and histone methylation (2021) (17)
- Vasoactive Intestinal Peptide Gene: Putative Mechanism of Information Storage at the RNA Level (1987) (17)
- Novel ADNP Syndrome Mice Reveal Dramatic Sex-Specific Peripheral Gene Expression With Brain Synaptic and Tau Pathologies (2021) (17)
- Distribution and regulation of vasoactive intestinal peptide mRNA and binding sites in the mammalian eye, brain and pituitary (1992) (16)
- Identification of the ‘estrogen‐induced protein’ in uterus and brain of untreated immature rats (1979) (16)
- Acquired immune deficiency syndrome and the developing nervous system. (1990) (16)
- Anti-inflammatory Effects of the Octapeptide NAP in Human Microbiota-Associated Mice Suffering from Subacute Ileitis (2018) (16)
- ADNP: in search for molecular mechanisms and innovative therapeutic strategies for frontotemporal degeneration (2015) (15)
- Does SCFD1 rs10139154 Polymorphism Decrease Alzheimer’s Disease Risk? (2019) (15)
- Neuropeptide receptor transcripts are expressed in the rat clitoris and oscillate during the estrus cycle in the rat vagina (2005) (15)
- The characterization and phosphorylation of an actin-like protein in synaptosomal membranes. (1980) (14)
- Atypical Auditory Brainstem Response and Protein Expression Aberrations Related to ASD and Hearing Loss in the Adnp Haploinsufficient Mouse Brain (2019) (14)
- NAP protects against cyanide-related microtubule destruction (2009) (14)
- A vasoactive intestinal peptide receptor analog alters the expression of homeobox genes. (2002) (14)
- Biosynthesis and Regulation of Expression. The Vasoactive Intestinal Peptide Gene (1988) (13)
- D-SAL and NAP: Two Peptides Sharing a SIP Domain (2016) (13)
- Immune-modulatory Properties of the Octapeptide NAP in Campylobacter jejuni Infected Mice Suffering from Acute Enterocolitis (2020) (13)
- ADNP: A major autism mutated gene is differentially distributed (age and gender) in the songbird brain (2015) (13)
- Neuropeptide Regulation of Mitosis (1994) (12)
- Anti-Inflammatory Properties of NAP in Acute Toxoplasma Gondii-Induced Ileitis in Mice (2015) (12)
- ADNP, a Microtubule Interacting Protein, Provides Neuroprotection Through End Binding Proteins and Tau: An Amplifier Effect (2018) (12)
- The 'estrogen-induced protein': quantitation by autoradiography of polyacrylamide gels. (1976) (12)
- Stress Genes in the Nervous System During Development and Aging Diseases (1998) (12)
- Analysis of HCRTR2, GNB3, and ADH4 Gene Polymorphisms in a Southeastern European Caucasian Cluster Headache Population (2019) (12)
- Activity-dependent neuroprotective protein (ADNP) is an alcohol-responsive gene and negative regulator of alcohol consumption in female mice (2018) (11)
- ADNP/ADNP2 expression in oligodendrocytes: implication for myelin-related neurodevelopment (2015) (11)
- The National Autism Database of Israel: a Resource for Studying Autism Risk Factors, Biomarkers, Outcome Measures, and Treatment Efficacy (2020) (11)
- Microtubule-Tau Interaction as a Therapeutic Target for Alzheimer’s Disease (2016) (11)
- NAP Protects against Tau Hyperphosphorylation Through GSK3. (2019) (11)
- Antagonism of VIP-stimulated cyclic AMP formation in chick brain (2003) (11)
- Microbiota changes associated with ADNP deficiencies: rapid indicators for NAP (CP201) treatment of the ADNP syndrome and beyond (2020) (11)
- Properties and synthesis of tubulin in neuroblastoma cells. (1976) (11)
- A Fatty Neuropeptide: Potential Drug for Noninvasive Impotence Treatment in a Rat Model (1993) (11)
- Neuropeptides: brain messengers of many faces (2001) (11)
- ADNP Regulates Cognition: A Multitasking Protein (2018) (10)
- Multiple Actions of a Hybrid PACAP Antagonist: Neuronal Cell Killing and Inhibition of Sperm Motility a (1998) (10)
- 3R tau expression modifies behavior in transgenic mice (2010) (10)
- Chapter 20:Davunetide (NAP) Pharmacology: Neuroprotection and Tau (2010) (10)
- Specific protein biomarker patterns for Alzheimer’s disease: improved diagnostics in progress (2017) (10)
- A Splice Variant to PACAP Receptor That Is Involved in Spermatogenesis Is Expressed in Astrocytes (2006) (10)
- Protection Against Developmental Deficiencies by a Lipophilic VIP Analogue (1998) (10)
- Tau Diagnostics and Clinical Studies (2017) (10)
- VIP and PACAP: novel approaches to brain functions and neuroprotection. (2011) (10)
- Sexual divergence in activity‐dependent neuroprotective protein impacting autism, schizophrenia, and Alzheimer's disease (2017) (10)
- SH3- and actin-binding domains connect ADNP and SHANK3, revealing a fundamental shared mechanism underlying autism (2022) (9)
- Tau as a drug target in Alzheimer’s disease (2002) (9)
- The increased proliferation of cultured neuroblastoma cells treated with vasoactive intestinal peptide is enhanced by simultaneous inhibition of neutral endopeptidase (2002) (9)
- The alpha-subunit of tubulin is preferentially associated with brain presynaptic membrnae. (1979) (9)
- Regulation of VIP gene expression in general. Human lung cancer cells in particular. (1996) (9)
- NEUROTROPHIC ACTION OF VIP : FROM CNS ONTOGENY TO THERAPEUTIC STRATEGY (1998) (8)
- Receptors for VIP and PACAP in guinea pig cerebral cortex (2007) (8)
- Age and Sex-Dependent ADNP Regulation of Muscle Gene Expression Is Correlated with Motor Behavior: Possible Feedback Mechanism with PACAP (2020) (8)
- The effects of vascular intrauterine growth retardation on cortical astrocytes (2010) (8)
- A Novel Microtubule-Tau Association Enhancer and Neuroprotective Drug Candidate: Ac-SKIP (2019) (8)
- RGS2 expression predicts amyloid-β sensitivity, MCI and Alzheimer's disease: genome-wide transcriptomic profiling and bioinformatics data mining (2017) (7)
- Novel extended and branched N-terminal analogs of VIP (2006) (7)
- Tau pathology: predictive diagnostics, targeted preventive and personalized medicine and application of advanced research in medical practice (2010) (7)
- Transcription of the vasoactive intestinal peptide gene in response to glucocorticoids: differential regulation of alternative transcripts is modulated by a labile protein in rat anterior pituitary (1997) (7)
- Activity-dependent neuroprotective protein (ADNP)-end-binding protein (EB) interactions regulate microtubule dynamics toward protection against tauopathy. (2020) (7)
- Peptides as drug candidates against Alzheimer's disease (2002) (7)
- Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations. (2019) (7)
- Decreased M1 muscarinic receptor density in rat amphetamine model of schizophrenia is normalized by clozapine, but not haloperidol (2008) (6)
- Early perceptual loss in depression (2007) (6)
- Vasoactive Intestinal Peptide Releases Interleukin‐1 from Astrocytes (1996) (6)
- Development of VIP Agonists and Antagonists with Tissue and Receptor Specificity: Effects on Behavioral Maturation, Sexual Function, and the Biologic Clock a (1996) (6)
- Deciphering the Enigma: NAP (CP201) the Active ADNP Drug Candidate Enters Cells by Dynamin-Associated Endocytosis (2020) (6)
- Regulation of VIP gene expression in general (2007) (6)
- Putative Blood Somatic Mutations in Post-Traumatic Stress Disorder-Symptomatic Soldiers: High Impact of Cytoskeletal and Inflammatory Proteins. (2021) (6)
- Single-cell analysis of cytoskeleton dynamics: From isoelectric focusing to live cell imaging and RNA-seq (2019) (5)
- Novel analogs of VIP with multiple C-terminal domains (2007) (5)
- Neuroprotective Drug Development: The Story of ADNP, NAP (Davunetide), and SKIP (2017) (5)
- Sex-and Region-Dependent Expression of the Autism-Linked ADNP Correlates with Social- and Speech-Related Genes in the Canary Brain (2020) (5)
- Therapeutic Potential of Vasoactive Intestinal Peptide and its Derivative Stearyl-Norleucine-VIP in Inflammation-Induced Osteolysis (2021) (5)
- ADNP differentially interact with genes/proteins in correlation with aging: a novel marker for muscle aging (2019) (5)
- PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP)/VASOACTIVE INTESTINAL PEPTIDE (VIP) RECEPTOR SUBTYPES IN RAT TISSUES: INVESTIGATION OF RECEPTOR BINDING, A NOVEL VIP RECEPTOR ANTAGONIST AND CHEMICAL CROSS-LINKING (1994) (4)
- Apolipoprotein E knockout mice as a model of behavioral dysfunction (2007) (4)
- STOP Codon Mutations at Sites of Natural Caspase Cleavage Are Implicated in Autism and Alzheimer’s Disease: The Case of ADNP (2022) (4)
- A Different Outlook at Psychiatric and Neurological Diseases: Brain Somatic Mutations Are Implicated in Schizophrenia (2021) (4)
- Outdoor Air Pollutant Concentration and COVID-19 Infection in Wuhan, China (2020) (4)
- Molecular Chaperones and Cell Signalling: Neuroendocrine Aspects of the Molecular Chaperones ADNF and ADNP (2005) (4)
- Introduction to the Special Issue on Spinal and Bulbar Muscular Atrophy (2016) (4)
- Summer neuropeptide conference The 3rd joint meeting of the summer neuropeptide conference (13th annual meeting) and the European Neuropeptide Club (13th annual meeting) Montauk, NY, June 8–12, 2003 (2003) (4)
- Study of NAP adsorption and assembly on the surface of HOPG (2014) (4)
- VIP/PACAP-Based Drug Development: The ADNP/NAP-Derived Mirror Peptides SKIP and D-SKIP Exhibit Distinctive in vivo and in silico Effects (2020) (4)
- Activity-dependent neuroprotective protein (ADNP): from autism to Alzheimer’s disease (2015) (4)
- Single Cell ADNP Predictive of Human Muscle Disorders: Mouse Knockdown Results in Muscle Wasting (2020) (4)
- Oral microbiota signatures in post-traumatic stress disorder (PTSD) veterans (2022) (3)
- Primary Cell Cultures and Cell Lines (2008) (3)
- Vineland Adaptive Behavior Scale in a Cohort of Four ADNP Syndrome Patients Implicates Age-Dependent Developmental Delays with Increased Impact of Activities of Daily Living (2022) (3)
- Outdoor PM2.5 concentration and rate of change in COVID-19 infection in provincial capital cities in China (2020) (3)
- Intranasal Delivery of Bioactive Peptides or Peptide Analogues Enhances Spatial Memory and Protects Against Cholinergic Deficits (2001) (3)
- Correction to: The Compassionate Side of Neuroscience: Tony Sermone’s Undiagnosed Genetic Journey—ADNP Mutation (2018) (3)
- VIP–PACAP 2010: My Own Perspective on Modulation of Cognitive and Emotional Behavior (2010) (3)
- Twelfth Annual Summer Neuropeptide Conference, June 29–July 3, 2002, Marco Island, Florida, USA (2002) (3)
- Neuropeptide GPCRs in neuroendocrinology: the case of activity-dependent neuroprotective protein (ADNP) (2012) (3)
- Activity-Dependent Neuroprotective Protein (ADNP) and Davunetide (NAP) (2013) (3)
- Estrogen regulation of vasoactive intestinal peptide mRNA in rat hypothalamus (2008) (3)
- RGS2 and SIRT1 Link Renin Angiotensin Aldosterone System to Alzheimer’s Disease (2017) (3)
- Correlation Between the Bilingual Status and the Onset Age of AD and MCI Subjects: Evidence from the ADNI Dataset (2021) (2)
- O4-04-03: A neuronal microtubule-interacting agent, nap, reduces hyperphosphorylated Tau and insoluble Tau, and enhances cognitive function in a transgenic mouse model of Alzheimer's disease (2008) (2)
- Protection against developmental and learning impairments in apolipoprotein e-deficient mice by activity-dependent femtomolar-acting peptides (1997) (2)
- The cytoplasmic localization of ADNP through 14-3-3 promotes sex-dependent neuronal morphogenesis, cortical connectivity, and calcium signaling (2023) (2)
- Protein synthesis in nuclei (2002) (2)
- Davunetide (AL-108): Targeting tangles (2009) (2)
- In memory of victor mutt (1998) (2)
- NAP ameliorates Alzheimer’s pathology in ad model mouse (2006) (2)
- The role of vasoactive intestinal peptide in neuroprotection: interview with Professor Illana Gozes (2007) (2)
- Activity-dependent neuroprotective protein (ADNP)/NAP (CP201): Autism, schizophrenia, and Alzheimer’s disease (2020) (2)
- Parkinson Disease-Modification Encompassing Rotenone and 6-Hydroxydopamine Neurotoxicity by the Microtubule-Protecting Drug Candidate SKIP (2021) (2)
- Inge Grundke-Iqbal, Ph.D. (1937–2012): the Discoverer of the Abnormal Hyperphosphorylation of Tau in Alzheimer’s Disease (2013) (2)
- Distinct Impairments Characterizing Different ADNP Mutants Reveal Aberrant Cytoplasmic-Nuclear Crosstalk (2022) (2)
- De Novo, Post-Zygotic, Inter-Tissue Mosaicism of Cell Autonomous ADNP Mutations in Autistic Individuals: Restricted Environmental Contribution (2022) (2)
- Chromatin remodeler Activity-Dependent Neuroprotective Protein (ADNP) contributes to syndromic autism (2023) (1)
- Revealing the role of activity dependent neuroprotective protein during embryogenesis (2006) (1)
- Poster Abstracts (2014) (1)
- Molecular Mechanisms of Cognitive Impairment and Intellectual Disability—Virtual ESN Mini-Conference in Conjunction with the FENS Forum, July 11–15, 2020 (2020) (1)
- 48 Differential expression of embryonic and maternal activity dependent neuroprotective protein (ADNP) during development (2001) (1)
- Improving replicability using interaction with laboratories: a multi-lab experimental assessment (2021) (1)
- S4-04-03 Protecting the brain by nasal peptide delivery: From concept to the clinic (2006) (1)
- The neuroprotective effect of activity dependent neurotrophic protein in mice after closed head injury (1997) (1)
- Activity-dependent neuroprotective protein (ADNP) is regulated in the brains of mouse models of human tauopathies: Toward davunetide replacement therapy (2010) (1)
- Preventive Treatment of Alzheimer’s Disease (1998) (1)
- The role of vasoactive intestinal peptide in neuroprotection: Professor Illana Gozes is interviewed by Emma Quigley. (2007) (1)
- Preventive, personalized medicine at the level of key regulatory proteins: updates on activity-dependent neuroprotective protein (ADNP) as a case study (2014) (1)
- Editorial: Designing a Protocol Adopting an Artificial Intelligence (AI)–Driven Approach for Early Diagnosis of Late-Onset Alzheimer’s Disease (2021) (1)
- Abstracts of the 15th Annual Meeting of the Israel Society for Neuroscience Eilat, Israel, December 3–5, 2006 (2006) (1)
- Higher ATM expression in lymphoblastoid cell lines from centenarian compared with younger women (2022) (1)
- Lipophilic vasoactive intestinal peptide: Potential drug for non-invasive impotence treatment (1993) (1)
- Blockade of VIP function in early mouse embryo induces severe microcephaly (1994) (1)
- Alzheimer's disease: my point of view. (2001) (1)
- A femtomolar-acting activity-dependent neuroprotective protein (ADNP) (1997) (1)
- International Meeting Molecular Neurodegeneration: News and Views in Molecular Neuroscience in Health and Disease. Delmenhorst, Germany, July 20–22, 2015 (2015) (1)
- Erratum to: The Compassionate Side of Neuroscience: Tony Sermone’s Undiagnosed Genetic Journey—ADNP Mutation (2016) (1)
- Protein synthesis in nuclei: when did the story start? (2002) (1)
- VIP and PACAP receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database (2019) (1)
- Pharmaceutical VIP: Prospects and Problems (1999) (1)
- Methods for single-cells (2019) (1)
- From the Desk of the Editor-in-Chief Journal of Molecular Neuroscience: Frontotemporal Dementias with the Face to Future Research and Development (2011) (1)
- A human homologue for activity-dependent neuroprotective protein (1997) (1)
- Molecular identification of the VIP/PACAP neuroprotection receptor (1997) (1)
- Journal of Molecular Neuroscience: Impacting Our Brains (2014) (1)
- Neuroprotective Treatment With NAP Reduces Laser–Induced Retinal Damage in Rats (2006) (1)
- The Neuropeptide NAP Provides Neuroprotection of Retinal Ganglion Cells After Optic Nerve Crush and Retinal Ischemia in vivo (2007) (1)
- 375 Experimental vascular intrauterine growth retardation is associated with altered cortical astrocytogenesis and developmental delays (1999) (0)
- Summer Neuropeptide Conference: The 14th Annual Meeting of the Summer Neuropeptide Conference, Miami Beach, Florida, USA, July 5–9, 2004 (2005) (0)
- Davunetide affects axonal transport in vivo (2012) (0)
- Analysis of ADNF-9 and NAP neuroprotection in human neurons: Relevance for Alzheimer disease and down syndrome therapies (2006) (0)
- Proceedings: In vitro translation of rat brain mRNA coding for tubulin and actin. (1975) (0)
- P1-251 NAP: neuroprotection through interaction with microtubules (2004) (0)
- ACTIVITY-DEPENDENT NEUROPROTECTIVE PROTEIN (ADNP): MARKING ALZHEIMER'S DISEASE AND SCHIZOPHRENIA (2014) (0)
- Report on the 12th Meeting of the European Neuropeptide Club, Olsztyn, Poland, May 22-25, 2002 (2002) (0)
- Highly active VIP - antagonists (1995) (0)
- Transfection of DNA into Cells (2008) (0)
- VIP, novel proteins and neuronal survival (2001) (0)
- Erratum to: The Compassionate Side of Neuroscience: Tony Sermone’s Undiagnosed Genetic Journey—ADNP Mutation (2016) (0)
- Vip-related peptides for treatment of sexual dysfunction in women (2001) (0)
- ADNP differentially interact with genes/proteins in correlation with aging: a novel marker for muscle aging (2019) (0)
- VIP: Design and synthesis of novel analogs and elucidating potential mechanisms affecting sexual function (2006) (0)
- NAP enhances tau-microtubule interactions and microtubule polymerization under zinc intoxication. (2013) (0)
- Deciphering the Enigma: NAP (CP201) the Active ADNP Drug Candidate Enters Cells by Dynamin-Associated Endocytosis (2020) (0)
- Neuropeptides 2003 (2007) (0)
- The Pregnant Spontaneously Rat as a Model of Asymmetric Intrauterine Growth Retardation and Neurodevelopmental Delay (2005) (0)
- CHAPTER 27 – TUBULIN IN THE NERVOUS SYSTEM (1985) (0)
- Tau Diagnostics and Clinical Studies (2017) (0)
- A multi-lab experimental assessment reveals that replicability can be improved by using empirical estimates of genotype-by-lab interaction. (2023) (0)
- D-NAP Prophylactic Treatment in the SOD Mutant Mouse Model of Amyotrophic Lateral Sclerosis: Review of Discovery and Treatment of Tauopathy (2012) (0)
- VASOACTIVE INTESTINAL POLYPEPTIDE—FROM GENE TO PROTEIN TO PEPTIDE (1982) (0)
- PACAP, VIP, and ADNP: Autism and Schizophrenia (2016) (0)
- A novel davunetide (NAPVSIPQQ to NAPVSIPQE) point mutation in activity-dependent neuroprotective protein (ADNP) causes a mild developmental syndrome. (2023) (0)
- Protecting against the outcome of taupathy: NAP – from concept to the clinic (2006) (0)
- SIRT1, miR-132 and miR-212 link human longevity to Alzheimer’s Disease (2018) (0)
- Advances and technical standards in neurosurgery (2003) (0)
- Vasoactive Intestinal Peptide: From Molecular Genetics to Neurotropism (1993) (0)
- VIP-and PACAP-Related Neuroprotection (2006) (0)
- Erratum to: Inge Grundke-Iqbal, Ph.D. (1937–2012): the Discoverer of the Abnormal Hyperphosphorylation of Tau in Alzheimer’s Disease (2013) (0)
- S4-02-04: NAP/SMALL molecule neurotrophics (2008) (0)
- Erratum to: Inge Grundke-Iqbal, Ph.D. (1937–2012): the Discoverer of the Abnormal Hyperphosphorylation of Tau in Alzheimer’s Disease (2013) (0)
- From the Desk of the Editor‑in‑Chief: Excerpts from the Society for Neurochemistry (ESN) Future Perspectives for European Neurochemistry Highlighting the Symposium Asking “Autism, Epilepsy, Intellectual Disability Where Do These All Meet?” (2022) (0)
- NAP (AL-108): A novel drug candidate for the treatment of Alzheimer’s disease (2005) (0)
- NAP protects cognition in the disrupted in schizophrenia (mutated DISC1) mouse mode (2017) (0)
- ADNP/ADNP2 expression in oligodendrocytes: implication for myelin-related neurodevelopment (2015) (0)
- International Meeting Molecular Neurodegeneration: News and Views in Molecular Neuroscience in Health and Disease. Delmenhorst, Germany, July 20–22, 2015 (2015) (0)
- Corrigendum: A Novel Microtubule-Tau Association Enhancer and Neuroprotective Drug Candidate: Ac-SKIP (2021) (0)
- ADNF mixtures for improving learning and memory function (2001) (0)
- Neuropeptides in the new millennium (2002) (0)
- A novel approach to Alzheimer's disease treatment: Intranasal application of neuroprotective peptide fragments (2000) (0)
- Neuropeptides and skin cell function: VIP and stearyl-[Nle17]VIP effects on HaCaT cells (2002) (0)
- Neuroprotection and the cytoskeleton: updates on the drug candidate, davunetide (2011) (0)
- P1-433 NAP: a novel compound toward clinical development in Alzheimer's disease (2004) (0)
- Specific protein biomarker patterns for Alzheimer’s disease: improved diagnostics in progress (2017) (0)
- Developmental Phenotype of the Rare Case of DJ Caused by a Unique ADNP Gene De Novo Mutation (2019) (0)
- NAP (davunetide) mechanism of microtubule/autophagy protection: discovery of new therapeutic targets and pipeline products (2014) (0)
- P4-333 NAP reduces phosphorylated tau in AD transgenic mice (2006) (0)
- Erratum to: Poster Abstracts (2012) (0)
- Somatic Mutations and Alzheimer's Disease. (2022) (0)
- Journal of Molecular Neuroscience: Impacting Our Brains (2014) (0)
- D-SAL and NAP: Two Peptides Sharing a SIP Domain (2016) (0)
- LEARNING DEFICIENCIES IN TRANSGENIC MICE WITH REDUCED BRAIN VASOACTIVE INTESTINAL PEPTIDE (1994) (0)
- 8th international symposium on VIP, PACAP related peptides. Introduction. (2008) (0)
- Cellular and animal models of skin alterations in the autism-related ADNP syndrome (2019) (0)
- The Compassionate Side of Neuroscience: Tony Sermone’s Undiagnosed Genetic Journey—ADNP Mutation (2015) (0)
- Vasoactive intestinal peptide (VIP) gene expression in the suprachiasmatic nucleus-the biological pacemaker (1989) (0)
- Neuroscience collaborations meeting report (2003) (0)
- Fifth International Symposium on Signal Transduction in Health and Disease (STADY V) (2010) (0)
- From Concept to Potential Therapeutics: Neuroprotective Peptides (2007) (0)
- Microtubule-Tau Interaction as a Therapeutic Target for Alzheimer’s Disease (2016) (0)
- In Memory of Our Teacher, Dr. Akira Arimura (2008) (0)
- The Future for Dementia Research: a Perspective from the Journal of Molecular Neuroscience (2016) (0)
- Antibody Production: Activity-Dependent Neuroprotective Protein (ADNP) as an Example (2008) (0)
- NAP Alpha-Aminoisobutyric Acid (IsoNAP) (2013) (0)
- Erratum to: Poster Abstracts (2012) (0)
- VIP conjugates and their active fragments having hydrophobic moieties and topical Zuberetungen for use in the treatment of male impotence. (1989) (0)
- Inge Grundke-Iqbal, Ph.D. (1937–2012): the Discoverer of the Abnormal Hyperphosphorylation of Tau in Alzheimer’s Disease (2013) (0)
- Tau Pathology: A Selected View on the Current Status (2013) (0)
- The Design, Synthesis, and Biological Evaluation of VIP and VIP Analogs (2008) (0)
- Young Investigator Award: Derek B. Oien (Supervisor: Jackob Moskovitz), University of Kansas (2009) (0)
- Structure and expression of the vasoactive intestinal peptide (VIP) gene (1985) (0)
- Correction to: The Compassionate Side of Neuroscience: Tony Sermone’s Undiagnosed Genetic Journey—ADNP Mutation (2018) (0)
- Abstracts of the 16th Annual Meeting of The Israel Society for Neuroscience Eilat, Israel, November 25–27, 2007 (2008) (0)
- The Future for Dementia Research: a Perspective from the Journal of Molecular Neuroscience (2016) (0)
- Atypical Auditory Brainstem Response and Protein Expression Aberrations Related to ASD and Hearing Loss in the Adnp Haploinsufficient Mouse Brain (2019) (0)
- VIP, novel proteins and peptide-mediated neuronal survival (2002) (0)
- Preventive, personalized medicine at the level of key regulatory proteins: updates on activity-dependent neuroprotective protein (ADNP) as a case study (2014) (0)
- Modified VIP derivatives and pharmaceutical compositions containing them (1992) (0)
- An Expert-guided Hierarchical Graph Attention Network for Post-traumatic Stress Disorder Highlyassociative Genetic Biomarkers Identification (2023) (0)
- Autism, Schizophrenia and Alzheimer’s Disease : a common thread from neuropeptides to brain regulating genes (2017) (0)
- Introduction to the Special Issue on Spinal and Bulbar Muscular Atrophy (2016) (0)
- Davunetide: Targeting Microtubule Dynamics in Dementia Clinical Trials (2010) (0)
- New derivative of vasoacitive intestinal peptide (1992) (0)
- Neurotrophic Action of VIP (2020) (0)
- Neuropeptides: From Bench to Bedside. (2019) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Illana Gozes?
Illana Gozes is affiliated with the following schools:
